TRIO - Translational Research in Oncology’s Post

In this #PeerExchange, experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes. Learn more about the groundbreaking treatments here: https://bit.ly/3WdkGsj #BreastCancer

Experts examine the efficacy and safety profiles of elacestrant, an oral selective estrogen receptor degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advantages in metastatic breast cancer treatment. Watch the video series to learn more: https://bit.ly/3WdkGsj #ManagedCare #BreastCancer

Alan Held's battle with stage-four prostate cancer saw a promising turn through theranostics in Germany, after traditional treatments showed limited success. This innovative approach, combining diagnostics and therapy, led to significant reductions in his cancer. Alan's journey, supported by his family and the expertise of Dr. Frankis Almaguel, is a testament to the potential of precision medicine. Notably, theranostics for prostate cancer care has now received FDA approval in the US, with Privado Health emerging as a leader in this field. For more details, visit the full story- https://lnkd.in/d2B-C_MJ #CancerWarrior #TheranosticsTriumph #ProstateCancerAwareness #HopeInHealing #PrecisionMedicine #InnovateToCure #FDAApprovedTherapy #SurvivorStories #PrivadoHealth #FightCancerWithInnovation #HealthInnovationLeaders #CuttingEdgeCure #EmpoweredPatientJourney #WholeHealth #BeatCancer

Insightful article shared by Clarivate for Life Sciences & Healthcare Oncology team published in Nature Drug Discovery!! Our authors mention in the article "Between 2023 and 2032, the market will become increasingly crowded, with novel drugs expected to gain approval." Click below to read more. #Clarivateoncology #oncology #targetedtherapy #HER2positive #triplenegative

#ASCO24 starts today! Check out the latest data showing how Precede Biosciences' comprehensive epigenomic #LiquidBiopsy platform accurately predicted HER2 status for patients with breast, gastroesophageal, and ovarian cancers and ER-status and ER pathway activation for patients with advanced breast cancer. #PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment #OncoAlert

Prostate cancer is the second leading cause of cancer-related death in American men, and there is a clear need for early detection and treatment advances. We’re excited to be at the American Urological Association 2024 Annual Meeting, supporting the metastatic castration-resistant #ProstateCancer (mCRPC) community with new real-world data to help inform clinical decision-making and improve treatment options for people affected by prostate cancer. Together we can #OutdoCancer. #AUA24 #ProstateCancer

We've just published our study that could revolutionize treatment options for unresectable appendiceal adenocarcinoma (AA). A first of its kind, our phase 2 study examines the efficacy and safety of combining atezolizumab with bevacizumab (Atezo+Bev) in battling advanced AA. With limited options available, our research offers a beacon of hope where previously there was little. This pioneering study leverages the synergy of VEGF and PD-1 inhibition—a strategy that’s shown promise in other tumor types—to potentially pioneer a new path for AA treatments. It's a stride forward in precision medicine, offering a personalized and targeted approach for a disease that has long been an orphan in the cancer treatment landscape. To read more about the outcomes: https://lnkd.in/dEY4tuAH #Oncology #ClinicalResearch #MedicalInnovation #CancerCare #Atezolizumab #Bevacizumab

We can act now to positively impact clinical research that leads to better treatment options for the women we love most. Participating in Lilly clinical trials for early-stage estrogen receptor positive and human epidermal receptor 2 negative (ER+/HER2-) breast cancer is one way to take action in finding better treatments. Start by learning more about Lilly clinical trials focused on advancing the treatment of breast cancer at https://e.lilly/49tmgtH. #MyStyleMatters #BlackHealthMatters #BreastCancerSurvivor #ClinicalTrials #BreastCancer #BreastCancerAwareness #CancerSupport #BreastCancerJourney #LifeAfterCancer #BlackWomenWithBreastCancer #CancerAwareness #BreastCancerWarrior #CancerFighter #PinkRibbon #SaveASister #BreastCancerResearch #IWishIKnew

Patient-reported outcomes (PROs) provide valuable insights into the real-life experiences of patients undergoing cancer treatment. By integrating PROs into cancer research, we can better understand patient needs and improve future treatments. Learn more: https://bit.ly/3X9nLJS #CancerResearch #PatientOutcomes #Oncology #PatientIQ

Together with our partner Jazz Pharmaceuticals, we are proud to share updated data from a Phase 2a trial of an investigational HER2-targeted, bispecific antibody in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic #breastcancer, presented today during #SABCS23. Metastatic breast cancer is an aggressive and devastating disease, and these late-breaking data further reinforce the potential to address some of the greatest unmet needs in #cancer with #HER2 expression.